Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity

Nature

Volumn 521, Issue 7550, 2015, Pages 99-104

  Carmi, Yaron ^a   Spitzer, Matthew H ^a,b   Linde, Ian L ^a   Burt, Bryan M ^a   Prestwood, Tyler R ^a   Perlman, Nicola ^a   Davidson, Matthew G ^a   Kenkel, Justin A ^a   Segal, Ehud ^a   Pusapati, Ganesh V ^a   Bhattacharya, Nupur ^a   Engleman, Edgar G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; TUMOR ANTIGEN; ALLOANTIBODY; CANCER ANTIBODY; CD40 ANTIGEN; FC RECEPTOR; TUMOR NECROSIS FACTOR;

ANTIBODY; CANCER; CELL ORGANELLE; ECOLOGICAL MODELING; IMMUNE RESPONSE; IMMUNITY; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR REJECTION; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; T LYMPHOCYTE;

MUS;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD40; ANTIGENS, NEOPLASM; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, IGG; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929075047     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14424     Document Type: Article

References (31)

1. Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286-291 (2013).
2. Grivennikov, S. I., Greten, F.R.&Karin,M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
3. Hanahan, D.&Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
4. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
5. Vesely, M. D., Kershaw, M. H., Schreiber, R. D. & Smyth, M. J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271 (2011).
6. Manning, T. C. et al. Antigen recognition and allogeneic tumor rejection in CD81 TCR transgenic/RAG2/2 mice. J. Immunol. 159, 4665-4675 (1997).
7. Ferrara, J., Guillen, F. J., Sleckman, B., Burakoff, S. J. & Murphy, G. F. Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinicaldisease. J. Invest.Dermatol. 86, 371-375 (1986).
8. Appelbaum, F. R. Haematopoietic cell transplantation as immunotherapy. Nature 411, 385-389 (2001).
9. Bishop, M. R. et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol. 22, 3886-3892 (2004).
10. Goulmy, E. Minor histocompatibility antigens: allo target molecules for tumorspecific immunotherapy. Cancer J. 10, 1-7 (2004).
11. Tseng, W. W. et al. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin. Cancer Res. 16, 3684-3695 (2010).
12. Dankort, D. et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 41, 544-552 (2009).
13. Qin, Z. et al. B cells inhibit induction of T cell-dependent tumor immunity. Nature Med. 4, 627-630 (1998).
14. de Visser, K. E., Korets, L. V. & Coussens, L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005).
15. Andreu, P. et al. FcRc activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17, 121-134 (2010).
16. Gerber, J. S. & Mosser, D. M. Reversing lipopolysaccharide toxicity by ligating the macrophage Fcc receptors. J. Immunol. 166, 6861-6868 (2001).
17. Willimsky, G. et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205, 1687-1700 (2008).
18. Soussi, T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60, 1777-1788 (2000).
19. Gumus, E. et al. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int. J. Urol. 11, 1070-1077 (2004).
20. Li, Q. et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17, 4987-4995 (2011).
21. DiLillo, D. J., Yanaba, K. & Tedder, T. F. B cells are required for optimal CD41 and CD81 T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184, 4006-4016 (2010).
22. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. & Ravetch, J. V. Fc receptors are requiredin passive and activeimmunity tomelanoma.Proc.NatlAcad. Sci.USA95, 652-656 (1998).
23. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
24. Hamanaka, Y. et al. Circulating anti-MUC1IgGantibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 103, 97-100 (2003).
25. Kurtenkov, O. et al. Humoral immune response to MUC1 and to the Thomsen- Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol. 46, 316-323 (2007).
26. Schuurhuis, D. H. et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176, 4573-4580 (2006).
27. Regnault, A. et al. Fcc receptor-mediated inductionof dendritic cellmaturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380 (1999).
28. Rafiq, K., Bergtold, A. & Clynes, R. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110, 71-79 (2002).
29. Schachter, J. et al. Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann. NY Acad. Sci. 1110, 305-314 (2007).
30. Fishman, P., Bar-Yehuda, S.&Shoenfeld, Y. IVIg to prevent tumormetastases. Int. J. Oncol. 21, 875-880 (2002).
31. Irish, J. et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc. Natl. Acad. Sci. USA 29, 12747-12754 (2010).